Page last updated: 2024-11-04

temozolomide and Seizures

temozolomide has been researched along with Seizures in 23 studies

Seizures: Clinical or subclinical disturbances of cortical function due to a sudden, abnormal, excessive, and disorganized discharge of brain cells. Clinical manifestations include abnormal motor, sensory and psychic phenomena. Recurrent seizures are usually referred to as EPILEPSY or seizure disorder.

Research Excerpts

ExcerptRelevanceReference
" In a previously-published multi-centre randomized clinical trial of 562 elderly glioblastoma patients, temozolomide plus short-course radiotherapy conferred a survival benefit over radiotherapy alone."9.34Temozolomide and seizure outcomes in a randomized clinical trial of elderly glioblastoma patients. ( Brandes, AA; Cairncross, JG; Climans, SA; Ding, K; Fay, M; Laperriere, N; Mason, WP; Menten, J; Nishikawa, R; O'Callaghan, CJ; Perry, JR; Phillips, C; Roa, W; Wick, W; Winch, C, 2020)
"The aim of this study was to assess the efficacy of temozolomide in patients with World Health Organisation (WHO) grade II gliomas treated with surgery alone using imaging and clinical criteria."9.10Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas. ( Abson, C; Ashley, S; Brada, M; Britton, J; Gonsalves, A; Hines, F; Sardell, S; Traish, D; Viviers, L; Westbury, C; Wilkins, P, 2003)
"Forty-three patients affected with LGG (29 astrocytoma, four oligodendroglioma and 10 mixed oligo-astrocytoma) were treated with temozolomide (TMZ) at the time of documented clinical and radiological progression."9.10Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response. ( Canalini, P; Carapella, CM; Carosi, M; Cianciulli, AM; Galiè, E; Giannarelli, D; Jandolo, B; Pace, A; Telera, S; Vidiri, A, 2003)
"Glioblastoma multiforme (GBM) is an aggressive brain tumor, often occurring with seizures managed with antiepileptic drugs, such as levetiracetam (LEV)."8.12Association of plasma levetiracetam concentration, MGMT methylation and sex with survival of chemoradiotherapy-treated glioblastoma patients. ( Banchi, M; Bocci, G; Cucchiara, F; Danesi, R; Di Paolo, A; Giannini, N; Giorgi, FS; Luci, G; Orlandi, P; Pasqualetti, F, 2022)
"We aimed to analyze the value of seizure reduction and radiological response as prognostic markers of survival in patients with low-grade glioma (LGG) treated with temozolomide (TMZ) chemotherapy."7.83Seizure reduction is a prognostic marker in low-grade glioma patients treated with temozolomide. ( Dirven, L; Heimans, JJ; Koekkoek, JA; Postma, TJ; Reijneveld, JC; Taphoorn, MJ; Vos, MJ, 2016)
"Valproic acid (VA) is an antiepileptic drug (AED) and histone deacetylase (HDAC) inhibitor taken by patients with glioblastoma (GB) to manage seizures, and it can modulate the biologic effects of radiation therapy (RT)."7.79Valproic acid use during radiation therapy for glioblastoma associated with improved survival. ( Barker, CA; Beal, K; Bishop, AJ; Chan, TA; Chang, M, 2013)
"To examine the efficacy of valproic acid (VPA) given either with or without levetiracetam (LEV) on seizure control and on survival in patients with glioblastoma multiforme (GBM) treated with chemoradiation."7.79Effect of valproic acid on seizure control and on survival in patients with glioblastoma multiforme. ( Dielemans, JC; Kerkhof, M; Taphoorn, MJ; van Breemen, MS; Vecht, CJ; Walchenbach, R; Zwinkels, H, 2013)
"Fresh suspected glioblastoma tissue was collected during surgery, and patients with pathology-confirmed GBM enrolled before starting concurrent Radiation Therapy and Temozolomide (RT/TMZ) with Intent to Treat (ITT) after recovery from RT/TMZ."5.51Phase 2 study of AV-GBM-1 (a tumor-initiating cell targeted dendritic cell vaccine) in newly diagnosed Glioblastoma patients: safety and efficacy assessment. ( Abedi, M; Aiken, RD; Bota, DA; Bota, PG; Carrillo, JA; Dillman, RO; Duma, CM; Hsieh, C; Hsu, FPK; Keirstead, HS; Kesari, S; Kong, XT; LaRocca, RV; Nistor, GI; Piccioni, DE; Taylor, TH, 2022)
"Seizures are a common symptom in patients with low-grade glioma (LGG), negatively influencing quality of life, if uncontrolled."5.42Seizure reduction in a low-grade glioma: more than a beneficial side effect of temozolomide. ( Dirven, L; Heimans, JJ; Koekkoek, JA; Postma, TJ; Reijneveld, JC; Taphoorn, MJ; Vos, MJ, 2015)
"All patients had seizure disorders that were treated with anticonvulsants."5.37Impact of temozolomide chemotherapy on seizure frequency in patients with low-grade gliomas. ( Moldovan, K; Pouratian, N; Schiff, D; Shaffrey, ME; Sherman, JH; Starke, RM; Yeoh, HK, 2011)
" In a previously-published multi-centre randomized clinical trial of 562 elderly glioblastoma patients, temozolomide plus short-course radiotherapy conferred a survival benefit over radiotherapy alone."5.34Temozolomide and seizure outcomes in a randomized clinical trial of elderly glioblastoma patients. ( Brandes, AA; Cairncross, JG; Climans, SA; Ding, K; Fay, M; Laperriere, N; Mason, WP; Menten, J; Nishikawa, R; O'Callaghan, CJ; Perry, JR; Phillips, C; Roa, W; Wick, W; Winch, C, 2020)
"The aim of this study was to assess the efficacy of temozolomide in patients with World Health Organisation (WHO) grade II gliomas treated with surgery alone using imaging and clinical criteria."5.10Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas. ( Abson, C; Ashley, S; Brada, M; Britton, J; Gonsalves, A; Hines, F; Sardell, S; Traish, D; Viviers, L; Westbury, C; Wilkins, P, 2003)
"Forty-three patients affected with LGG (29 astrocytoma, four oligodendroglioma and 10 mixed oligo-astrocytoma) were treated with temozolomide (TMZ) at the time of documented clinical and radiological progression."5.10Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response. ( Canalini, P; Carapella, CM; Carosi, M; Cianciulli, AM; Galiè, E; Giannarelli, D; Jandolo, B; Pace, A; Telera, S; Vidiri, A, 2003)
"Glioblastoma multiforme (GBM) is an aggressive brain tumor, often occurring with seizures managed with antiepileptic drugs, such as levetiracetam (LEV)."4.12Association of plasma levetiracetam concentration, MGMT methylation and sex with survival of chemoradiotherapy-treated glioblastoma patients. ( Banchi, M; Bocci, G; Cucchiara, F; Danesi, R; Di Paolo, A; Giannini, N; Giorgi, FS; Luci, G; Orlandi, P; Pasqualetti, F, 2022)
"We aimed to analyze the value of seizure reduction and radiological response as prognostic markers of survival in patients with low-grade glioma (LGG) treated with temozolomide (TMZ) chemotherapy."3.83Seizure reduction is a prognostic marker in low-grade glioma patients treated with temozolomide. ( Dirven, L; Heimans, JJ; Koekkoek, JA; Postma, TJ; Reijneveld, JC; Taphoorn, MJ; Vos, MJ, 2016)
"Valproic acid (VA) is an antiepileptic drug (AED) and histone deacetylase (HDAC) inhibitor taken by patients with glioblastoma (GB) to manage seizures, and it can modulate the biologic effects of radiation therapy (RT)."3.79Valproic acid use during radiation therapy for glioblastoma associated with improved survival. ( Barker, CA; Beal, K; Bishop, AJ; Chan, TA; Chang, M, 2013)
"To examine the efficacy of valproic acid (VPA) given either with or without levetiracetam (LEV) on seizure control and on survival in patients with glioblastoma multiforme (GBM) treated with chemoradiation."3.79Effect of valproic acid on seizure control and on survival in patients with glioblastoma multiforme. ( Dielemans, JC; Kerkhof, M; Taphoorn, MJ; van Breemen, MS; Vecht, CJ; Walchenbach, R; Zwinkels, H, 2013)
"Glioblastoma is almost always incurable and most older patients survive less than 6 months."2.53How I treat glioblastoma in older patients. ( Mohile, NA, 2016)
"We identified the preoperative seizure frequency threshold by plotting a receiver operating characteristic curve."1.56Short-term outcomes and predictors of post-surgical seizures in patients with supratentorial low-grade gliomas. ( Chen, Q; Deng, G; Gao, L; Jiang, H; Liu, B; Tan, Y; Wang, J; Yang, K; Yuan, F, 2020)
"Controlling seizures is essential during GBM treatment because they are often present and closely associated with the quality of life of GBM patients."1.51Effect of anti-epileptic drugs on the survival of patients with glioblastoma multiforme: A retrospective, single-center study. ( Chang, MJ; Min, KL; Ryu, JY, 2019)
"Seizures are a common symptom in patients with low-grade glioma (LGG), negatively influencing quality of life, if uncontrolled."1.42Seizure reduction in a low-grade glioma: more than a beneficial side effect of temozolomide. ( Dirven, L; Heimans, JJ; Koekkoek, JA; Postma, TJ; Reijneveld, JC; Taphoorn, MJ; Vos, MJ, 2015)
"Thromboembolic events, seizures, neurologic symptoms and adverse effects from corticosteroids and chemotherapies are frequent clinical complications seen in Glioblastoma (GB) patients."1.42Risk factors for glioblastoma therapy associated complications. ( Brenke, C; Capper, D; Ening, G; Osterheld, F; Schmieder, K, 2015)
"Clinical presentation of gliomatosis cerebri is variable and depends on the degree, extent, and location of cortical involvement."1.39Bilateral ptosis as initial presentation of gliomatosis cerebri: case report. ( Braca, J; Kovanda, T; Prabhu, V, 2013)
"All patients had seizure disorders that were treated with anticonvulsants."1.37Impact of temozolomide chemotherapy on seizure frequency in patients with low-grade gliomas. ( Moldovan, K; Pouratian, N; Schiff, D; Shaffrey, ME; Sherman, JH; Starke, RM; Yeoh, HK, 2011)
"Temozolomide is an effective treatment for seizure control in patients with brain tumors."1.37Seizure control: a secondary benefit of chemotherapeutic temozolomide in brain cancer patients. ( Hu, A; Kesari, S; Kim, RY; Lee, JW; Nguyen, A; Xu, Z, 2011)

Research

Studies (23)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (13.04)29.6817
2010's15 (65.22)24.3611
2020's5 (21.74)2.80

Authors

AuthorsStudies
Cucchiara, F1
Luci, G1
Giannini, N1
Giorgi, FS1
Orlandi, P1
Banchi, M1
Di Paolo, A1
Pasqualetti, F1
Danesi, R1
Bocci, G1
Bota, DA2
Taylor, TH2
Piccioni, DE2
Duma, CM2
LaRocca, RV2
Kesari, S3
Carrillo, JA2
Abedi, M2
Aiken, RD2
Hsu, FPK2
Kong, XT2
Hsieh, C2
Bota, PG2
Nistor, GI2
Keirstead, HS2
Dillman, RO2
Ryu, JY1
Min, KL1
Chang, MJ1
Jiang, H1
Liu, B1
Deng, G1
Yuan, F1
Tan, Y1
Yang, K1
Gao, L1
Wang, J2
Chen, Q1
Climans, SA1
Brandes, AA1
Cairncross, JG1
Ding, K1
Fay, M1
Laperriere, N1
Menten, J1
Nishikawa, R1
O'Callaghan, CJ1
Perry, JR1
Phillips, C1
Roa, W1
Wick, W1
Winch, C1
Mason, WP1
Jiao, Y1
Wang, M1
Liu, X1
Wang, Z1
Luo, W1
Yu, Y1
Sun, H1
Kovanda, T1
Braca, J1
Prabhu, V1
Barker, CA1
Bishop, AJ1
Chang, M1
Beal, K1
Chan, TA1
Kerkhof, M1
Dielemans, JC1
van Breemen, MS1
Zwinkels, H1
Walchenbach, R1
Taphoorn, MJ3
Vecht, CJ1
Koekkoek, JA2
Dirven, L2
Heimans, JJ2
Postma, TJ2
Vos, MJ2
Reijneveld, JC2
Rees, J1
Ening, G1
Osterheld, F1
Capper, D1
Schmieder, K1
Brenke, C1
Roelcke, U1
Wyss, MT1
Nowosielski, M1
Rudà, R2
Roth, P1
Hofer, S1
Galldiks, N1
Crippa, F1
Weller, M1
Soffietti, R2
Mohile, NA1
Toler, J1
Deputy, S1
Zakris, E1
Bégué, RE1
Pellerino, A1
Sherman, JH1
Moldovan, K1
Yeoh, HK1
Starke, RM1
Pouratian, N1
Shaffrey, ME1
Schiff, D1
Hu, A1
Xu, Z1
Kim, RY1
Nguyen, A1
Lee, JW1
Davis, ME1
Stoiber, AM1
Brada, M1
Viviers, L1
Abson, C1
Hines, F1
Britton, J1
Ashley, S1
Sardell, S1
Traish, D1
Gonsalves, A1
Wilkins, P1
Westbury, C1
Pace, A1
Vidiri, A1
Galiè, E1
Carosi, M1
Telera, S1
Cianciulli, AM1
Canalini, P1
Giannarelli, D1
Jandolo, B1
Carapella, CM1
Menniti, A1
Moschettoni, L1
Liccardo, G1
Lunardi, P1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Randomized Phase III Study of Temozolomide and Short-Course Radiation Versus Short-Course Radiation Alone In The Treatment of Newly Diagnosed Glioblastoma Multiforme in Elderly Patients[NCT00482677]Phase 3562 participants (Actual)Interventional2007-11-14Completed
The Prospective Trial for Validation of the Role of Levetiracetam as a Sensitizer of Temozolomide in the Treatment of Newly Diagnosed Glioblastoma Patients[NCT02815410]Phase 273 participants (Anticipated)Interventional2016-07-31Not yet recruiting
A Prospective Cohort to Study the Effect of Postoperative Upfront Temozolomide Chemotherapy on IDH Mutational Low Grade Gliomas in Eloquent Areas[NCT02209428]Phase 254 participants (Actual)Interventional2014-06-30Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Methylation Status of the O6-methylguanine-DNA Methyltransferase Promoter

Overall survival for patients by Methylation status of the O6-methylguanine-DNA methyltransferase promoter (NCT00482677)
Timeframe: 7 years

InterventionMonths (Median)
Temozolomide13.47
Radiation7.69

Overall Survival

Time from date of randomization to the date of death of any causes, or censored at last known alive date. (NCT00482677)
Timeframe: 7 years

InterventionMonths (Median)
Temozolomide9.33
Radiation7.62

Progression-free Survival

Time from date of randomization to the date of disease progression or death whichever came first, or censored at last disease assessment date. (NCT00482677)
Timeframe: 7 years

InterventionMonths (Median)
Temozolomide5.29
Radiation3.94

Reviews

2 reviews available for temozolomide and Seizures

ArticleYear
How I treat glioblastoma in older patients.
    Journal of geriatric oncology, 2016, Volume: 7, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Antineoplastic Agents, Alkylating; Biomarkers, Tumo

2016
Glioblastoma multiforme: enhancing survival and quality of life.
    Clinical journal of oncology nursing, 2011, Volume: 15, Issue:3

    Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Dacarbazine; Glioblastoma; Humans; Neoplas

2011

Trials

4 trials available for temozolomide and Seizures

ArticleYear
Phase 2 study of AV-GBM-1 (a tumor-initiating cell targeted dendritic cell vaccine) in newly diagnosed Glioblastoma patients: safety and efficacy assessment.
    Journal of experimental & clinical cancer research : CR, 2022, Dec-14, Volume: 41, Issue:1

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dendritic Cells; Gliobl

2022
Phase 2 study of AV-GBM-1 (a tumor-initiating cell targeted dendritic cell vaccine) in newly diagnosed Glioblastoma patients: safety and efficacy assessment.
    Journal of experimental & clinical cancer research : CR, 2022, Dec-14, Volume: 41, Issue:1

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dendritic Cells; Gliobl

2022
Phase 2 study of AV-GBM-1 (a tumor-initiating cell targeted dendritic cell vaccine) in newly diagnosed Glioblastoma patients: safety and efficacy assessment.
    Journal of experimental & clinical cancer research : CR, 2022, Dec-14, Volume: 41, Issue:1

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dendritic Cells; Gliobl

2022
Phase 2 study of AV-GBM-1 (a tumor-initiating cell targeted dendritic cell vaccine) in newly diagnosed Glioblastoma patients: safety and efficacy assessment.
    Journal of experimental & clinical cancer research : CR, 2022, Dec-14, Volume: 41, Issue:1

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dendritic Cells; Gliobl

2022
Temozolomide and seizure outcomes in a randomized clinical trial of elderly glioblastoma patients.
    Journal of neuro-oncology, 2020, Volume: 149, Issue:1

    Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Female; Follow-Up Studi

2020
Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2003, Volume: 14, Issue:12

    Topics: Administration, Oral; Adult; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease Progressio

2003
Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2003, Volume: 14, Issue:12

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease Prog

2003

Other Studies

17 other studies available for temozolomide and Seizures

ArticleYear
Association of plasma levetiracetam concentration, MGMT methylation and sex with survival of chemoradiotherapy-treated glioblastoma patients.
    Pharmacological research, 2022, Volume: 181

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; DNA

2022
Effect of anti-epileptic drugs on the survival of patients with glioblastoma multiforme: A retrospective, single-center study.
    PloS one, 2019, Volume: 14, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Antineoplastic Agents, Alkylating; Brai

2019
Short-term outcomes and predictors of post-surgical seizures in patients with supratentorial low-grade gliomas.
    Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2020, Volume: 72

    Topics: Adult; Brain Neoplasms; Cohort Studies; Electroencephalography; Female; Glioma; Humans; Magnetic Res

2020
Clinical Features and Prognostic Factors of Pediatric Glioblastoma: Report of 38 Cases.
    World neurosurgery, 2021, Volume: 153

    Topics: Adolescent; Antineoplastic Agents, Alkylating; Apraxias; Brain Neoplasms; Chemoradiotherapy, Adjuvan

2021
Bilateral ptosis as initial presentation of gliomatosis cerebri: case report.
    Journal of neurological surgery. Part A, Central European neurosurgery, 2013, Volume: 74 Suppl 1

    Topics: Anticonvulsants; Antineoplastic Agents, Alkylating; Blepharoptosis; Brain Neoplasms; Chemoradiothera

2013
Valproic acid use during radiation therapy for glioblastoma associated with improved survival.
    International journal of radiation oncology, biology, physics, 2013, Jul-01, Volume: 86, Issue:3

    Topics: Adolescent; Adult; Aged; Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combin

2013
Effect of valproic acid on seizure control and on survival in patients with glioblastoma multiforme.
    Neuro-oncology, 2013, Volume: 15, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms;

2013
Seizure reduction in a low-grade glioma: more than a beneficial side effect of temozolomide.
    Journal of neurology, neurosurgery, and psychiatry, 2015, Volume: 86, Issue:4

    Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease-

2015
Temozolomide in low-grade gliomas: living longer and better.
    Journal of neurology, neurosurgery, and psychiatry, 2015, Volume: 86, Issue:4

    Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioma; Humans; Male; Seizu

2015
Risk factors for glioblastoma therapy associated complications.
    Clinical neurology and neurosurgery, 2015, Volume: 134

    Topics: Age Factors; Antineoplastic Agents; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Cohort Studies; Da

2015
Seizure reduction is a prognostic marker in low-grade glioma patients treated with temozolomide.
    Journal of neuro-oncology, 2016, Volume: 126, Issue:2

    Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Femal

2016
Amino acid positron emission tomography to monitor chemotherapy response and predict seizure control and progression-free survival in WHO grade II gliomas.
    Neuro-oncology, 2016, Volume: 18, Issue:5

    Topics: Adult; Amino Acids; Antineoplastic Agents; Area Under Curve; Brain Neoplasms; Dacarbazine; Disease-F

2016
Cognitive Dysfunction After Cranial Radiation for a Brain Tumor.
    Journal of the Pediatric Infectious Diseases Society, 2016, Volume: 5, Issue:1

    Topics: Acyclovir; Antineoplastic Agents, Alkylating; Antiviral Agents; Brain Stem Neoplasms; Cognitive Dysf

2016
Does valproic acid affect tumor growth and improve survival in glioblastomas?
    CNS oncology, 2016, Volume: 5, Issue:2

    Topics: Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Differentiation; Cell Prol

2016
Impact of temozolomide chemotherapy on seizure frequency in patients with low-grade gliomas.
    Journal of neurosurgery, 2011, Volume: 114, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chi-Square Distribution; Dacarbazin

2011
Seizure control: a secondary benefit of chemotherapeutic temozolomide in brain cancer patients.
    Epilepsy research, 2011, Volume: 95, Issue:3

    Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Electroencephal

2011
Low-grade primary meningeal lymphoma: case report and review of the literature.
    Neurosurgical review, 2005, Volume: 28, Issue:3

    Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Gliobl

2005